21st Century Dermatopathology: Molecular Diagnostics for Melanocytic Neoplasms
Ata Moshiri, MD, MPH Assistant Professor Department of Medicine, Division of Dermatology Department of Laboratory Medicine and Pathology University of Washington Objectives: - Identify key driver mutations and secondary malignant mutations in melanocytic neoplasms.
- Recognize the utility of next-generation sequencing and other advanced molecular diagnostic techniques for borderline melanocytic proliferations.
- Become familiar with the term “melanocytoma” as an intermediate grade melanocytic proliferation.
Speaker disclosures: Dr. Ata Moshiri discloses a financial relationship with Castle Biosciences [advisory board] within the past 24 months. Why Attend? Melanocytic tumors of uncertain malignant potential (MelTUMPs) and other borderline melanocytic neoplasms have long posed a significant challenge to pathologists and clinicians, and expose patients to under- or over-treatment and surveillance, thus leading to significant anxiety. The World Health Organization 4th Edition (2018) reclassified melanocytic tumors on the basis of not just histomorphology, but initiating and driver mutations, and introduced benign (i.e., nevus), intermediate (i.e., melanocytoma), and malignant classifications for each of the familiar phylogenies of melanocytic tumors. Next-generation sequencing (NGS) has allowed for identification of initiating driver mutations, as well as secondary genomic alterations known to be important to melanomagenesis, and has allowed for improved classification and prognostication of the biologic behavior of borderline melanocytic neoplasms. We will discuss several such cases from the University of Washington Dermatopathology service with the aim of highlighting the importance of uniting histopathologic and molecular data in modern dermatopathology. Meeting ID: 931 1873 4050
Passcode: PGR2122 You must sign-in on the following form to receive CME credit. Sign-in online: https://forms.gle/W2oE8d3MYbnyTDe58
Planning Committee Disclosure: The following members have not had any financial relationships with any ineligible entities in the past 24 months: Drs. Rebecca Alvarez, Eleanor Chen, Lisa Koch, Jose Mantilla, Elizabeth Parker, Maria Tretiakova, Larry True, James Malleis, and Trent Irwin. The following members disclose financial relations with ineligible entities within the past 24 months: Dr Shreeram Akilesh discloses a financial relationship (speaker honorarium) with GoldfinchBio, Inc.; Dr. Haodong Xu discloses a financial relationship with PathomIQ (consultant). All relevant financial relationships listed have been mitigated.
Grant Acknowledgment: None
CME Accreditation statement: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Washington School of Medicine designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. (Each session is 1.0 credit) |